Navigation Links
Isis Reports Financial Results and Highlights for First Quarter 2012
Date:5/8/2012

, and are designed to provide long-term control in patients who cannot control their glucose levels with existing therapies.  With type 2 diabetes being the most rapidly growing epidemic worldwide, we believe bringing forward novel medicines to add to the treatment paradigm for these patients is a wise investment," continued Ms. Parshall.  

"In summary, we have begun another productive year in which we expect to report data on many of the drugs in our pipeline, initiate larger, longer studies for our Factor XI and TTR drugs, and continue to move promising new drugs into our pipeline.
We look forward to KYNAMRO commercialization and bringing this important new medicine to patients in great need," concluded Ms. Parshall. 

Corporate and Drug Development Highlights

  • Genzyme submitted a new drug application for KYNAMRO in the United States for homozygous FH patients.
  • Dr. Raul Santos presented data from the long-term extension study of KYNAMRO at the International Symposium on Atherosclerosis.  The data highlight the long-term safety and efficacy of KYNAMRO in patients who have been treated with KYNAMRO.
  • Isis initiated a Phase 2 study on ISIS-APOCIIIRx in patients with elevated triglycerides and a Phase 1 study on ISIS-STAT3Rx in patients with cancer.
  • Isis reported data from a Phase 1 study of ISIS-TTRRx showing that ISIS-TTRRx produced statistically significant reductions in TTR protein.
  • Isis formed a new strategic alliance with Biogen Idec to develop and commercialize ISIS-SMNRx to treat Spinal Muscular Atrophy (SMA).  Isis received a $29 million upfront payment and is eligible to receive up to an additional $270 million in a license fee and milestone payments, and double-digit royalties on sales of ISIS-SMNRx.
  • Isis received Orphan Drug Designation for ISIS-SMNRx in Europe for the treatment of SMA.
  • OncoGenex reported preliminary positive Phase 1 d
    '/>"/>

  • SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Vanda Pharmaceuticals Reports First Quarter 2012 Results
    2. Landauer, Inc. Reports Fiscal 2012 Second Quarter Results
    3. Halozyme Reports First Quarter 2012 Financial Results
    4. MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results
    5. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
    6. IRIDEX Reports 2012 First Quarter Results
    7. Cambrex Reports First Quarter 2012 Results
    8. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
    9. Cumberland Pharmaceuticals Reports First Quarter 2012 Financial Results
    10. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
    11. Neuland Labs Reports Financial Results For Fiscal Year 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis , ... laser tattoo removal experience with the advanced Astanza Duality laser and ... quality cosmetic services with cutting edge medical technology and offering expert ... has seen a dramatic increase in the presence of ...
    (Date:1/14/2014)... LEESBURG, Va. , Jan. 14, 2014 Animal Emergency Critical ... in Leesburg, Virginia is the first in ... hyperbaric oxygen chamber. Dr. Susan M. Barnes ... years. Dr. Barnes and husband, Dr. Cole Taylor , are ...
    (Date:1/14/2014)... Inc. , a privately held company pioneering the development ... related neurodegenerative disorders, announced today the relocation of its ... as of January 15, 2014 and expanded lease agreement ... Oligomerix, which is focused on the development ...
    Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
    ... 2010 Renal Advantage and Liberty Dialysis, which last month ... dialysis services in the U.S., today announced that they have ... not disclosed – was completed on December 17, 2010.  The ... in 260 locations in 32 states. "The completion ...
    ... 22, 2010 Particle Sciences Inc. (PSI), a leading ... that, when coupled with an antigen, enhanced its immunogenicity, ... work is described in Vaccine , 2010 Dec. ... strong systemic and mucosal cellular and humoral immune responses ...
    Cached Medicine Technology:Renal Advantage and Liberty Dialysis Deal Completed 2Renal Advantage and Liberty Dialysis Deal Completed 3Particle Sciences Develops Wax Nanoparticles that Enhance Immune Response to Antigens 2
    (Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
    (Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
    (Date:4/17/2014)... researchers at UC Davis has shown that the cyclin ... cell division, also boosts the mitochondrial activity to power ... has been shown to perform both jobs. This newfound ... control cellular energy production, potentially advancing cancer care and ... the journal Developmental Cell . , "These proteins ...
    (Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
    (Date:4/17/2014)... days to find a colored ribbon representing a disease. A ... what color ribbon does one think of with lung cancer?, ... many suffering from the disease, black may be the only ... of lung cancer patients, primarily smokers between the ages of ... the stigma often felt by these patients, the emotional toll ...
    Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2Health News:Unraveling the 'black ribbon' around lung cancer 2
    ... , WASHINGTON, Dec. 8 The National Business Group on ... employers, announced today that Sally Welborn, Senior Vice President of ... Directors, effective immediately. , "We are thrilled to announce Sally,s ... Senior Vice President of Human Resources at Coca-Cola Enterprises ...
    ... , ... Technologies, Inc. , has been selected by the Blue Cross ... watchlist screening software for OFAC, OIG and EPLS and USA PATRIOT ... compliance software to BCBSA,s Chicago headquarters and its member Blue Cross ...
    ... , - May Set Stage ... Dec. 8 Neurology researchers have shown that feeding amino acids ... stage for the first effective treatment for cognitive impairments suffered by ... animal model that dietary intervention can restore a proper balance of ...
    ... panic disorder, study finds , TUESDAY, Dec. 8 (HealthDay ... in their blood might be at increased risk for ... , Researchers analyzed information on 1,987 adults, aged 20 ... Health and Nutrition Examination Survey between 1997 and 2004. ...
    ... defined as the pathological retrograde movement of gastric ... which may be important in reflux are observed ... disorder in these patients is ineffective esophageal motility ... been shown to be strongly associated with isolated ...
    ... to a lack of suitable studies, it is unclear ... autologous haematopoietic stem cell transplantation. With this type of ... are removed at a convenient time and generally re-implanted ... is neither indication nor proof of additional benefit compared ...
    Cached Medicine News:Health News:National Business Group on Health Elects Sally Welborn, Walmart Executive, to Board of Directors 2Health News:The National Blue Cross and Blue Shield Association Selects ATTUS Technologies as Preferred Provider for OFAC, OIG, EPLS and USA PATRIOT Act Compliance 2Health News:The National Blue Cross and Blue Shield Association Selects ATTUS Technologies as Preferred Provider for OFAC, OIG, EPLS and USA PATRIOT Act Compliance 3Health News:With Amino Acid Diet, Mice Improve After Brain Injury 2Health News:With Amino Acid Diet, Mice Improve After Brain Injury 3Health News:Lead Exposure May Affect Mental Health 2Health News:Are manometric findings different between the patients with erosive and nonerosive disease? 2Health News:Autologous stem cell transplantation for soft tissue sarcoma: insufficient research into therapy 2Health News:Autologous stem cell transplantation for soft tissue sarcoma: insufficient research into therapy 3Health News:Autologous stem cell transplantation for soft tissue sarcoma: insufficient research into therapy 4
    ... 3 mirror lenses featuring ultra-clear Volk 3-Mirror ... 76°, 66° and 60°. The 3 ... well central and peripheral fundus viewing and ... angled to eliminate gaps in the visualized ...
    ... are a family of single-use direct view vitrectomy ... particular region of the retinal surface during eye ... 1 gram and is formed and polished to ... human cornea. Lenses come in boxes of 10 ...
    ... AFX Lens is a direct ... in an air-filled eye. In ... a primary air-fluid exchange vitrectomy ... sutureless design make it well ...
    ... Prism are designed for midperipherical ... for tractional retinal detachments (PDR, ... detachment. They can be used ... midperipheral laser applications. Direct image ...
    Medicine Products: